A prospective observational clinical trial with case control study design to test the prognostic ability of a proprietary OncoDiscoverTM diagnostic technology designed to capture and concentrate circulating tumor cells (CTCs) in blood samples of patients with various carcinomas and its use to predict progression free survival (PFS) and disease free survival (DFS). (PROGCTC)

Actorius Innovations and Research Pvt Ltd0 sites0 target enrollmentStarted: TBDLast updated: November 24, 2021

Trial Snapshot

No summary available.

•1. Quasi-metastatic patients (stage II & stage III) suffering from the breast, colo-rectal, cervical, ovarian, esophageal / stomach and loco-regional (oral, larynx, tongue, head & neck etc.) cancers would be considered for the aforementioned trial.
•2. Males (lung, colorectal, esophageal, stomach, loco-regional) and/or females (Breast, ovarian, cervical, colorectal, esophageal, stomach, loco-regional).
•3. Patients who are yet to receive the treatment.
•4. Age > 18 years.
•5. Patients who are well counselled about the trial and from who written informed consent obtained.
•6. Confirmed diagnosis of Stage II or III cancer by oncologist.
•7. Able to undergo blood collection after diagnosis and prior to surgery and initiation of the therapy,
•8. Those patients, who would provide the blood sample after diagnosis, surgery and at the initiation, in the course of and at the end of the treatment.

•1. Patients unable to understand the research protocol and/or provide informed consent.
•2. Patients with known immunodeficiency, or pregnancy.
•3. Participation in another cancer screening trial.

Sponsor

Actorius Innovations and Research Pvt Ltd